Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence

Journal of Law, Medicine and Ethics 47 (3):381-387 (2019)
  Copy   BIBTEX

Abstract

The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.

Other Versions

No versions found

Links

PhilArchive

    This entry is not archived by us. If you are the author and have permission from the publisher, we recommend that you archive it. Many publishers automatically grant permission to authors to archive pre-prints. By uploading a copy of your work, you will enable us to better index it, making it easier to find.

    Upload a copy of this work     Papers currently archived: 102,283

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Translating Stem Cell Research: Challenges at the Research Frontier.David Magnus - 2010 - Journal of Law, Medicine and Ethics 38 (2):267-276.

Analytics

Added to PP
2019-09-28

Downloads
25 (#901,963)

6 months
7 (#694,161)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Spencer Hey
Harvard University

Citations of this work

Biomarker Validation: Context and Complexities.Lisa M. McShane - 2019 - Journal of Law, Medicine and Ethics 47 (3):388-392.

Add more citations

References found in this work

No references found.

Add more references